Neurotoxicity of Cancer Therapies
Advances in cancer treatment have dramatically improved survival across many tumor types, but these therapies carry significant neurologic risks. Neurotoxicity is among the most common dose-limiting side effects of cancer therapy and a leading cause of treatment discontinuation and long-term disability. The landscape of treatment-related neurotoxicity has expanded beyond traditional chemotherapy to include immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, targeted molecular agents, and radiation. Neurologists must be prepared to recognize these complications promptly, as early intervention can prevent irreversible neurologic damage and enable continued oncologic treatment when possible. This topic provides a comprehensive, practical guide to the neurotoxicity profiles of major cancer treatment modalities.
Bottom Line
- CIPN: Chemotherapy-induced peripheral neuropathy is the most common neurotoxicity of cancer treatment; duloxetine is the only agent with randomized evidence for treatment (CIPN study)
- Immune checkpoint inhibitors: Can cause de novo myasthenia gravis (often fulminant with myositis overlap), encephalitis, GBS, and transverse myelitis; hold ICI and start high-dose steroids immediately
- CAR-T neurotoxicity (ICANS): Immune Effector Cell-Associated Neurotoxicity Syndrome — encephalopathy, seizures, cerebral edema; graded by ICE score; treat with dexamethasone and anakinra
- Methotrexate: Three temporal patterns of neurotoxicity: acute (chemical meningitis), subacute (stroke-like episodes), and chronic (leukoencephalopathy)
- Radiation: Acute, early-delayed, and late-delayed toxicity; radiation necrosis vs. tumor recurrence is a critical diagnostic challenge (perfusion MRI, PET, MR spectroscopy)
- PRES: Posterior reversible encephalopathy syndrome can be triggered by multiple chemotherapeutic agents; headache, seizures, visual disturbance with characteristic posterior-predominant MRI changes
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is the most prevalent neurologic complication of systemic cancer therapy, affecting 30–70% of patients receiving neurotoxic chemotherapy. It is a major cause of dose reduction, treatment discontinuation, and long-term functional impairment. CIPN significantly impacts quality of life through pain, sensory loss, impaired balance, and reduced fine motor function.
| Agent Class | Specific Agents | Neuropathy Pattern | Key Features |
|---|---|---|---|
| Platinum compounds | Cisplatin, oxaliplatin, carboplatin | Sensory >> motor; large-fiber predominant | Cisplatin: cumulative, dose-dependent; dorsal root ganglionopathy; proprioceptive loss; “coasting” — neuropathy may worsen for weeks to months after drug cessation. Oxaliplatin: acute cold-triggered dysesthesias (unique) + chronic cumulative sensory neuropathy |
| Taxanes | Paclitaxel, docetaxel, cabazitaxel | Length-dependent sensory > motor | Microtubule disruption in axonal transport; paclitaxel most neurotoxic; painful neuropathy common; dose-dependent; onset within first few cycles |
| Vinca alkaloids | Vincristine, vinblastine | Motor > sensory (distinguishing feature) | Vincristine: distal weakness, foot drop, wrist drop; autonomic neuropathy (constipation, ileus); cranial neuropathy possible; cumulative; onset early in treatment |
| Proteasome inhibitors | Bortezomib, carfilzomib | Painful small-fiber neuropathy | Bortezomib: burning pain, allodynia; subcutaneous administration reduces neuropathy risk vs. IV; partially reversible with dose reduction |
| Immunomodulatory | Thalidomide, lenalidomide | Sensory, length-dependent | Thalidomide: cumulative, dose-dependent; may be irreversible; lenalidomide has lower neurotoxicity risk |
| Antibody-drug conjugates | Brentuximab vedotin, polatuzumab | Sensory > motor; length-dependent | Due to MMAE (auristatin) payload; similar to vinca alkaloid mechanism; generally reversible with dose modification |
Diagnosis of CIPN
- Clinical assessment: Total Neuropathy Score (TNS), CTCAE grading (Grade 1–4), patient-reported outcome measures (EORTC QLQ-CIPN20)
- Nerve conduction studies/EMG: Confirm axonal sensory neuropathy (reduced SNAP amplitudes); useful to establish baseline and monitor progression
- Key differential: Distinguish from paraneoplastic neuropathy (especially anti-Hu sensory neuronopathy), diabetic neuropathy, nutritional deficiencies (B12), and leptomeningeal disease
CIPN Management: Evidence-Based Approach
- Duloxetine 60 mg/day: The ONLY agent with Level A evidence for CIPN treatment (randomized crossover trial showed significant pain reduction vs. placebo)
- Dose modification: Primary strategy for prevention — dose reduction or treatment delay based on CTCAE grade
- Oxaliplatin acute syndrome: Avoid cold exposure; calcium/magnesium infusions may reduce acute symptoms (no effect on chronic CIPN)
- Subcutaneous bortezomib: Reduces CIPN incidence by ~25% compared to IV administration with equivalent efficacy
- Not recommended: Gabapentin, pregabalin, tricyclic antidepressants — insufficient evidence specifically for CIPN (though often used empirically)
- No proven preventive agents: Vitamin E, glutamine, acetyl-L-carnitine, alpha-lipoic acid, and amifostine have not shown consistent benefit in clinical trials
Cisplatin “Coasting” Phenomenon
- Cisplatin neuropathy may worsen for 2–6 months after drug discontinuation
- This “coasting” effect is due to ongoing platinum accumulation in dorsal root ganglia with slow clearance
- Clinicians and patients must be warned that neuropathy progression after stopping cisplatin does NOT indicate a new neurologic process
- Most coasting stabilizes by 6–12 months, though significant residual deficits are common
Immune Checkpoint Inhibitor (ICI) Neurotoxicity
Immune checkpoint inhibitors (anti-PD-1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab) have revolutionized oncology but produce immune-related adverse events (irAEs) in up to 60% of patients. Neurologic irAEs occur in approximately 1–5% of patients, but can be severe and life-threatening. Combination ICI therapy (anti-PD-1 + anti-CTLA-4) carries the highest risk.
| Neurologic irAE | Frequency | Clinical Features | Key Points |
|---|---|---|---|
| Myasthenia gravis | 0.1–0.2% (most common severe) | De novo MG; rapid onset; bulbar and respiratory predominant; often fulminant | Overlap with myositis in ~30% (elevated CK); overlap with myocarditis in ~10% (lethal triad); anti-AChR antibodies positive in ~65%; anti-striational antibodies common |
| Myositis | 0.4–1% | Proximal weakness, elevated CK (often >5000), myalgias; may involve ocular muscles (ptosis, diplopia) | Frequently overlaps with MG; cardiac involvement (myocarditis) must be excluded with troponin, ECG, echocardiogram |
| Encephalitis | 0.1–0.5% | Altered mental status, seizures, cognitive decline; may be limbic, diffuse, or brainstem | May be autoimmune antibody-positive (anti-NMDAR, anti-Ma2, anti-GAD65) or seronegative; MRI may show T2 changes in medial temporal lobes or be normal |
| Guillain-Barré syndrome | 0.1–0.3% | Ascending weakness, areflexia, CSF albuminocytologic dissociation | May progress faster than typical GBS; IVIG or PLEX preferred over steroids alone; monitor respiratory function closely |
| Aseptic meningitis | 0.1–0.5% | Headache, neck stiffness, photophobia; CSF lymphocytic pleocytosis | Often self-limited; more common with anti-CTLA-4 (ipilimumab); rule out leptomeningeal disease and infection |
| Transverse myelitis | <0.1% | Sensory level, paraparesis, bowel/bladder dysfunction | Rare but devastating; aggressive immunosuppression required |
| Cranial neuropathies | 0.1–0.5% | Facial nerve palsy most common; optic neuritis; hearing loss | Bilateral facial palsy should raise suspicion; exclude leptomeningeal disease |
| Peripheral neuropathy | 1–3% | Sensorimotor, length-dependent; may be demyelinating or axonal | Usually mild (Grade 1–2); severe cases rare; differentiate from CIPN if prior chemotherapy |
ICI-Myasthenia Gravis: The Lethal Triad
- ICI-triggered MG is often de novo (no prior MG history) and fulminant with rapid respiratory compromise
- Myasthenia + Myositis + Myocarditis overlap occurs in ~10% and carries >50% mortality
- Check CK, troponin, ECG, and echocardiogram in ALL patients with ICI-associated MG
- Immediate management: Hold ICI permanently, high-dose IV methylprednisolone (1 g/day × 3–5 days), early IVIG or PLEX
- Pyridostigmine alone is insufficient and may precipitate cholinergic crisis in ICI-MG
ICI Neurotoxicity Management Algorithm
| Grade | Clinical Features | Management |
|---|---|---|
| Grade 1 (mild) | Mild symptoms; no interference with daily activities | May continue ICI with close monitoring; consider holding ICI; neurology consultation |
| Grade 2 (moderate) | Moderate symptoms; some interference with daily activities | Hold ICI; oral prednisone 0.5–1 mg/kg/day; neurology referral; MRI/LP as indicated |
| Grade 3 (severe) | Severe symptoms; hospitalization required | Permanently discontinue ICI; IV methylprednisolone 1–2 mg/kg/day; consider IVIG or PLEX; ICU monitoring for MG/GBS |
| Grade 4 (life-threatening) | Life-threatening; urgent intervention required | Permanently discontinue ICI; IV methylprednisolone 1 g/day × 3–5 days; emergent PLEX or IVIG; ICU admission; intubation if respiratory failure |
CAR-T Cell Neurotoxicity (ICANS)
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies (DLBCL, ALL, mantle cell lymphoma, multiple myeloma). Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is the most common neurologic complication, occurring in 20–65% of patients depending on the CAR-T product and underlying disease. ICANS is believed to result from cytokine-mediated endothelial activation and blood-brain barrier disruption.
| Feature | Details |
|---|---|
| Onset | Typically 3–10 days after CAR-T infusion; often follows or co-occurs with cytokine release syndrome (CRS) |
| Clinical features | Encephalopathy (most common), aphasia/word-finding difficulty, tremor, seizures, cerebral edema (rare but potentially fatal) |
| ICE score | Immune Effector Cell-Associated Encephalopathy score: orientation (4 pts), naming (3 pts), following commands (1 pt), writing a sentence (1 pt), attention/counting (1 pt); total 10 points |
| ICANS Grade 1 | ICE 7–9: mild confusion, word-finding difficulty |
| ICANS Grade 2 | ICE 3–6: moderate encephalopathy, but arousable |
| ICANS Grade 3 | ICE 0–2: severe encephalopathy; clinical seizures; focal deficits |
| ICANS Grade 4 | Obtunded/comatose, status epilepticus, cerebral edema, papilledema |
| Risk factors | High tumor burden, preexisting neurologic conditions, high-grade CRS, elevated ferritin/IL-6/C-reactive protein |
ICANS Treatment
- Dexamethasone: First-line treatment for ICANS Grade ≥2; 10 mg IV every 6 hours for Grade 2–3; high-dose methylprednisolone (1 g/day) for Grade 4
- Tocilizumab (anti-IL-6R): Primary treatment for CRS but does NOT cross the BBB effectively; limited efficacy for isolated ICANS
- Anakinra (IL-1 receptor antagonist): Emerging evidence for refractory ICANS; crosses BBB better than tocilizumab; being evaluated in clinical trials
- Seizure prophylaxis: Levetiracetam 500–750 mg BID during the risk window (days 0–30) is commonly used at many centers
- Cerebral edema management: Rare but potentially fatal; high-dose steroids, hyperosmolar therapy, neurosurgical consultation for severe cases
ICE Score Assessment (Quick Reference)
- Orientation (4 points): Year, month, city, hospital — 1 point each
- Naming (3 points): Name 3 objects — 1 point each
- Following commands (1 point): “Close your eyes and open them”
- Writing (1 point): Ability to write a standard sentence
- Attention (1 point): Count backwards from 100 by 10s
- Total 10 points; perform at baseline and twice daily during CAR-T monitoring period
Methotrexate Neurotoxicity
Methotrexate (MTX) is a cornerstone of treatment for primary CNS lymphoma, ALL (CNS prophylaxis), and leptomeningeal disease. Its neurotoxicity follows three distinct temporal patterns that are critical to recognize.
| Pattern | Onset | Route | Clinical Features | Mechanism & Management |
|---|---|---|---|---|
| Acute | Hours to days | Intrathecal | Chemical meningitis: headache, nausea, vomiting, neck stiffness, fever; CSF pleocytosis | Aseptic inflammation of meninges; self-limited (24–72 hours); supportive care; does not preclude future intrathecal therapy |
| Subacute | Days to 2 weeks | IV (high-dose) or intrathecal | Stroke-like episodes: transient focal deficits (aphasia, hemiparesis), sometimes with seizures; MRI may show restricted diffusion (DWI+) | Transient focal demyelination; usually self-resolving within 48–72 hours; aminophylline (adenosine antagonist) may be preventive; does not predict chronic toxicity |
| Chronic | Months to years | IV or intrathecal (especially with concurrent/prior WBRT) | Leukoencephalopathy: progressive cognitive decline, gait ataxia, urinary incontinence (dementia triad); MRI shows diffuse periventricular white matter T2 hyperintensity | Irreversible white matter injury; risk markedly increased with concurrent/prior whole-brain radiation; no effective treatment; dose reduction or avoidance of WBRT is the only prevention |
Methotrexate + Whole-Brain Radiation: Synergistic Toxicity
- Concurrent or sequential high-dose MTX and WBRT dramatically increases the risk of severe, irreversible leukoencephalopathy
- Incidence of leukoencephalopathy: ~25% with combined MTX + WBRT vs. <5% with either alone
- In primary CNS lymphoma treatment, the trend has shifted toward deferring WBRT or using reduced-dose WBRT to minimize this risk
- Patients >60 years old are at highest risk for treatment-related leukoencephalopathy
Radiation Neurotoxicity
Radiation-induced neurotoxicity is classified by temporal onset into three categories, each with distinct pathophysiology and clinical significance. Differentiating late radiation necrosis from tumor progression is one of the most clinically important and challenging neuroimaging problems in neuro-oncology.
| Category | Onset | Clinical Features | Pathophysiology | Prognosis |
|---|---|---|---|---|
| Acute | During or within weeks of RT | Headache, nausea, worsening of pre-existing focal deficits, fatigue | Vasogenic edema; disrupted blood-brain barrier | Self-limited; responsive to corticosteroids |
| Early-delayed | 2–6 months post-RT | Somnolence syndrome (fatigue, drowsiness, especially in children after WBRT); transient worsening of MRI lesions (pseudoprogression); Lhermitte sign (after spinal RT) | Transient demyelination; resolves spontaneously | Self-limited (weeks to months); important to distinguish from true tumor progression |
| Late-delayed | >6 months post-RT (may occur years later) | Radiation necrosis: focal enhancing mass, seizures, progressive focal deficits. Cognitive decline: progressive memory and executive dysfunction. Leukoencephalopathy: diffuse white matter injury. Radiation-induced tumors: meningiomas, gliomas (decades later) | Vascular injury, fibrinoid necrosis, gliosis, white matter demyelination | Often irreversible; radiation necrosis may respond to bevacizumab; cognitive decline progressive |
Radiation Necrosis vs. Tumor Progression
Distinguishing radiation necrosis from tumor recurrence is a critical diagnostic challenge because both present as enhancing lesions on MRI. Multiple advanced imaging modalities can help differentiate these entities.
| Imaging Modality | Radiation Necrosis | Tumor Progression |
|---|---|---|
| Perfusion MRI (rCBV) | Low relative cerebral blood volume (hypoperfused) | High rCBV (hyperperfused, neoangiogenesis) |
| MR spectroscopy | High lipid-lactate peak; low choline; low choline/NAA ratio | Elevated choline; high choline/NAA ratio; elevated choline/creatine |
| FDG-PET | Hypometabolic (low FDG uptake) | Hypermetabolic (high FDG uptake; limited by high background cortical uptake) |
| Amino acid PET (FET, MET) | Low uptake | High uptake (more specific than FDG for brain tumors) |
| DWI/ADC | Variable; may show facilitated diffusion | Restricted diffusion in highly cellular tumor |
Bevacizumab for Radiation Necrosis
- Bevacizumab (anti-VEGF antibody) is the most effective medical treatment for symptomatic radiation necrosis
- Mechanism: reduces VEGF-driven vasogenic edema and vascular permeability in necrotic tissue
- Typical regimen: bevacizumab 7.5 mg/kg IV every 2–3 weeks for 4–6 cycles
- Response rate: >90% show radiographic improvement; significant steroid-sparing effect
- Randomized trial (Levin et al., 2011) demonstrated superiority over placebo for radiation necrosis
- Risks: hypertension, proteinuria, wound healing impairment, rare hemorrhage
Posterior Reversible Encephalopathy Syndrome (PRES)
PRES is an acute neurologic syndrome characterized by headache, seizures, visual disturbances, and altered mental status, with characteristic posterior-predominant vasogenic edema on neuroimaging. Multiple chemotherapeutic agents can trigger PRES through endothelial dysfunction.
PRES-Inducing Cancer Therapies
- Calcineurin inhibitors: Tacrolimus, cyclosporine (post-transplant setting)
- Anti-VEGF agents: Bevacizumab, sorafenib, sunitinib, pazopanib
- Cytotoxic chemotherapy: Cisplatin, cytarabine, methotrexate, gemcitabine
- Immune checkpoint inhibitors: Rare but reported
- CAR-T cell therapy: Associated with CRS/ICANS
Diagnosis and Management
- MRI: T2/FLAIR hyperintensity predominantly in parieto-occipital white matter; DWI typically shows facilitated diffusion (vasogenic edema); restricted diffusion suggests cytotoxic edema and worse prognosis
- Management: Discontinue offending agent, aggressive blood pressure control, antiepileptic drugs for seizures, magnesium sulfate (especially in eclampsia-related PRES)
- Prognosis: Usually reversible within days to weeks with appropriate treatment; permanent injury occurs in ~5–15% with hemorrhagic or cytotoxic edema variants
Ifosfamide Encephalopathy
| Feature | Details |
|---|---|
| Mechanism | Chloroacetaldehyde (neurotoxic metabolite) causes mitochondrial dysfunction; depletes brain glutathione |
| Onset | Hours to days after ifosfamide infusion |
| Clinical features | Confusion, somnolence, hallucinations, cerebellar ataxia, seizures; may progress to coma |
| EEG | Generalized slowing, triphasic waves (may mimic metabolic encephalopathy) |
| Risk factors | Renal impairment, low serum albumin, prior cisplatin, hepatic dysfunction, pelvic disease (altered drug metabolism) |
| Treatment | Methylene blue 50 mg IV every 4–6 hours (acts as alternative electron carrier in mitochondrial chain); thiamine supplementation |
| Prophylaxis | Methylene blue 50 mg IV TID during ifosfamide infusion prevents recurrence in patients with prior encephalopathy |
| Prognosis | Usually fully reversible within 48–72 hours with methylene blue; mortality <1% with prompt treatment |
Other Notable Neurotoxicities
| Agent | Neurotoxicity | Key Features |
|---|---|---|
| 5-Fluorouracil / Capecitabine | Cerebellar syndrome | Acute ataxia, dysarthria, nystagmus; due to dihydropyrimidine dehydrogenase (DPD) deficiency — genetic testing recommended before initiation; reversible with drug cessation |
| Cytarabine (high-dose) | Cerebellar toxicity | Pancerebellar syndrome at doses ≥3 g/m2; age >50 and renal impairment increase risk; may be irreversible (Purkinje cell loss); assess cerebellar function between doses |
| Intrathecal cytarabine | Arachnoiditis, myelopathy | Chemical arachnoiditis; co-administer dexamethasone to prevent; transverse myelopathy rare but devastating |
| Bevacizumab | PRES, hemorrhage, ischemic stroke | Anti-VEGF disrupts vascular homeostasis; monitor blood pressure; increased risk of intracranial hemorrhage in brain tumor patients |
| Ibrutinib | Intracranial hemorrhage | Subdural hematoma risk, especially with concurrent anticoagulation or antiplatelet agents; mechanism involves platelet dysfunction |
| Crizotinib/Lorlatinib | CNS effects | Lorlatinib: cognitive effects, mood changes, psychosis, vivid dreams (CNS-penetrant by design); crizotinib: visual disturbances |
| Fludarabine | Severe neurotoxicity at high doses | Delayed progressive encephalopathy, blindness, coma; rare at standard doses; irreversible at toxic doses |
| Intrathecal vincristine | FATAL | Intrathecal vincristine administration is universally fatal (ascending myeloencephalopathy); vincristine must NEVER be administered intrathecally — institutional safeguards mandatory |
Never-Event: Intrathecal Vincristine
- Intrathecal vincristine is uniformly fatal — causing ascending radiculomyeloencephalopathy and death
- This has been classified as a “never event” by patient safety organizations worldwide
- Institutional safeguards: vincristine must be dispensed in a minibag (not syringe), labeled “FOR IV USE ONLY,” and never co-transported with intrathecal medications
- WHO has issued specific recommendations to prevent this error
Comprehensive Toxicity Reference by Agent Class
| Agent Class | CNS Toxicity | PNS Toxicity | Other Neurologic |
|---|---|---|---|
| Platinum compounds | PRES, ototoxicity (cisplatin) | Sensory neuropathy (all), coasting (cisplatin), cold dysesthesias (oxaliplatin) | Lhermitte sign (cisplatin) |
| Taxanes | Encephalopathy (rare) | Sensory > motor neuropathy, myalgias | — |
| Vinca alkaloids | SIADH (vincristine) | Motor > sensory neuropathy, autonomic neuropathy | Cranial neuropathies, jaw pain |
| Methotrexate | Chemical meningitis, stroke-like episodes, leukoencephalopathy | — | Synergistic toxicity with WBRT |
| Checkpoint inhibitors | Encephalitis, meningitis, PRES | MG, myositis, GBS, neuropathy | Myocarditis overlap, cranial neuropathies |
| CAR-T cells | ICANS, seizures, cerebral edema | — | Aphasia, tremor |
| Radiation | Edema, pseudoprogression, radiation necrosis, leukoencephalopathy, cognitive decline | Brachial/lumbosacral plexopathy (late) | Radiation-induced tumors, vasculopathy |
| Anti-VEGF agents | PRES, intracranial hemorrhage | — | Stroke, wound healing impairment |
| Proteasome inhibitors | PRES (rare) | Painful small-fiber neuropathy | Herpes zoster reactivation |
References
- Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-1967.
- Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-1367.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768.
- Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1-8.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
- Chamberlain MC. Neurotoxicity of intrathecal methotrexate. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. 2nd ed. Elsevier; 2018:529-538.
- Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65(2):499-508.
- Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487-1495.
- Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925.
- Cavaliere R, Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep. 2006;6(3):218-226.
- Giglio P, Gilbert MR. Neurologic complications of cancer and its treatment. Curr Oncol Rep. 2010;12(1):50-59.
- Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291-294.
- Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549-1563.
- Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958-971.